Piramal

Piramal Pharma Solutions is a full-service, global CDMO offering integrated drug discovery, development, and manufacturing services. Founded in 2020, it leverages a significant global footprint and a team of over 4,700 to support innovators in small molecules, biologics, and complex modalities like ADCs and peptides. The company emphasizes patient-centricity, integrated solutions, and a strong quality culture, positioning itself as a strategic partner for pharmaceutical and biotech companies seeking to accelerate and de-risk their programs from concept to commercial supply.

Integrated CDMO services across drug discovery, development, and manufacturing for small molecules, biologics, peptides, and Antibody Drug Conjugates (ADCs). Leverages a 'Science Collective' of experts for innovation and problem-solving.

Operates in a highly competitive global CDMO market against large, diversified players like Lonza, Catalent, and Thermo Fisher Scientific, as well as numerous specialized niche competitors. Differentiation is achieved through integrated end-to-end services, specialized expertise in ADCs and peptides, and a strong emphasis on quality and customer partnership.